PS-1001 / Paratus Sciences - LARVOL DELTA

PS-1001, a Novel Pan-Inflammasome Inhibitor Targeting the Adaptor Protein ASC: A Platform Candidate for Inflammasome-Driven Inflammatory Diseases (ACR Convergence 2026) - "Broader anti-inflammatory activity was assessed ex vivo in the human 3D SeboSkin model with patient-derived tissue, using adalimumab as comparator. PS-1001 is a first-in-class, potent pan-inflammasome inhibitor targeting ASC, with preclinical evidence of activity across multiple inflammasome-driven models and broad suppression of inflammatory mediators in human ex vivo tissue. The integrated preclinical package supports advancement into IND-enabling studies with priority focus on genetically and mechanistically defined autoinflammatory syndromes where IL-1β and IL-18 co-dysregulation drives pathology."

Gastroenterology • Gastrointestinal Disorder • Gout • Inflammation • Inflammatory Arthritis • Psoriasis • IL18 • IL1B • NLRP3